Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The clinical trial will investigate the effect of brexpiprazole on the concept of life
engagement in patients with MDD with a current depressive episode.
Phase:
Phase 4
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators:
Lundbeck Canada Inc. Otsuka Canada Pharmaceutical Inc.